Correlation between sarcopenia and gastric cancer_West China Medical Journal

Authors：

HE Dong , FAN Wanli , ZHANG Shuze ,  CHENG Zhibin

Department of General Surgery, Lanzhou University Second Hospital, Lanzhou, Gansu 730030, P. R. China;

Corresponding author：

CHENG Zhibin, Email: zhibin_cheng@hotmail.com

Keywords：

Sarcopenia; gastric cancer; nutritional support; prognosis

DOI：

10.7507/1002-0179.202303035

Video：

Export PDF Favorites Scan Get Citation

Abstract Full text Figures/Tables Video References Cited by

Sarcopenia is a syndrome associated with reduced strength, mass and function of skeletal muscles. Aging of gastric cancer patients, lack of nutritional intake, and pathological mechanisms of gastric cancer increase the likelihood of sarcopenia. Sarcopenia is associated with the development of gastric cancer and may be a risk factor for the formation of gastric cancer. Sarcopenia is closely related to the prognosis and treatment of gastric cancer. At present, the treatment of sarcopenia is still in the exploratory stage, and more research is needed to obtain better treatment plans and improve the quality of life of patients. This article reviews the research status of sarcopenia and gastric cancer in order to provide evidence for clinical research.

Citation： HE Dong, FAN Wanli, ZHANG Shuze, CHENG Zhibin. Correlation between sarcopenia and gastric cancer. West China Medical Journal, 2023, 38(7): 1091-1095. doi: 10.7507/1002-0179.202303035 Copy

1.	Sung H, Ferlay J, Siegel RL, et al. Global Cancer Statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin, 2021, 71(3): 209-249.
2.	Cruz-Jentoft AJ, Bahat G, Bauer J, et al. Sarcopenia: revised European consensus on definition and diagnosis. Age Ageing, 2019, 48(1): 16-31.
3.	Juez LD, Priego P, Bajawi M, et al. Impact of sarcopenic obesity on long-term cancer outcomes and postoperative complications after gastrectomy for gastric cancer. J Gastrointest Surg, 2023, 27(1): 35-46.
4.	Kuwada K, Kuroda S, Kikuchi S, et al. Clinical impact of sarcopenia on gastric cancer. Anticancer Res, 2019, 39(5): 2241-2249.
5.	Kim YM, Kim JH, Baik SJ, et al. Sarcopenia and sarcopenic obesity as novel risk factors for gastric carcinogenesis: a health checkup cohort study. Front Oncol, 2019, 9: 1249.
6.	Petrelli F, Cortellini A, Indini A, et al. Association of obesity with survival outcomes in patients with cancer: a systematic review and meta-analysis. JAMA Netw Open, 2021, 4(3): e213520.
7.	De A, Kumari S, Kaur A, et al. Hand-grip strength as a screening tool for sarcopenia in males with decompensated cirrhosis. Indian J Gastroenterol, 2022, 41(3): 284-291.
8.	Cruz-Jentoft AJ, Sayer AA. Sarcopenia. Lancet, 2019, 393(10191): 2636-2646.
9.	Stringer HJ, Wilson D. The role of ultrasound as a diagnostic tool for sarcopenia. J Frailty Aging, 2018, 7(4): 258-261.
10.	Perkisas S, Baudry S, Bauer J, et al. Application of ultrasound for muscle assessment in sarcopenia: towards standardized measurements. Eur Geriatr Med, 2018, 9(6): 739-757.
11.	Gonzalez MC, Barbosa-Silva TG, Heymsfield SB. Bioelectrical impedance analysis in the assessment of sarcopenia. Curr Opin Clin Nutr Metab Care, 2018, 21(5): 366-374.
12.	Zhao WY, Zhang Y, Hou LS, et al. The association between systemic inflammatory markers and sarcopenia: results from the west china health and aging trend study (WCHAT). Arch Gerontol Geriatr, 2021, 92: 104262.
13.	Bullock AF, Greenley SL, McKenzie GAG, et al. Relationship between markers of malnutrition and clinical outcomes in older adults with cancer: systematic review, narrative synthesis and meta-analysis. Eur J Clin Nutr, 2020, 74(11): 1519-1535.
14.	Vaupel P, Multhoff G. Revisiting the Warburg effect: historical dogma versus current understanding. J Physiol, 2021, 599(6): 1745-1757.
15.	Tambay V, Raymond VA, Bilodeau M. MYC rules: leading glutamine metabolism toward a distinct cancer cell phenotype. Cancers (Basel), 2021, 13(17): 4484.
16.	Jiang P, Du W, Wang X, et al. p53 regulates biosynthesis through direct inactivation of glucose-6-phosphate dehydrogenase. Nat Cell Biol, 2011, 13(3): 310-316.
17.	Elson DA, Ryan HE, Snow JW, et al. Coordinate up-regulation of hypoxia inducible factor (HIF)-1alpha and HIF-1 target genes during multi-stage epidermal carcinogenesis and wound healing. Cancer Res, 2000, 60(21): 6189-6195.
18.	Akash MSH, Rehman K, Liaqat A. Tumor necrosis factor-alpha: role in development of insulin resistance and pathogenesis of type 2 diabetes mellitus. J Cell Biochem, 2018, 119(1): 105-110.
19.	Argilés JM, López-Soriano FJ, Busquets S. Mediators of cachexia in cancer patients. Nutrition, 2019, 66: 11-15.
20.	Tisdale MJ. Mechanisms of cancer cachexia. Physiol Rev, 2009, 89(2): 381-410.
21.	Mirza KA, Tisdale MJ. Functional identity of receptors for proteolysis-inducing factor on human and murine skeletal muscle. Br J Cancer, 2014, 111(5): 903-908.
22.	Abrigo J, Simon F, Cabrera D, et al. Mitochondrial dysfunction in skeletal muscle pathologies. Curr Protein Pept Sci, 2019, 20(6): 536-546.
23.	Roeland EJ, Bohlke K, Baracos VE, et al. Management of cancer cachexia: ASCO guideline. J Clin Oncol, 2020, 38(21): 2438-2453.
24.	Seki T, Yang Y, Sun X, et al. Brown-fat-mediated tumour suppression by cold-altered global metabolism. Nature, 2022, 608(7922): 421-428.
25.	Nguyen TD, Miyatake Y, Yoshida T, et al. Tumor-secreted proliferin-1 regulates adipogenesis and lipolysis in cachexia. Int J Cancer, 2020, 148(8): 1982-1992.
26.	Tural U, Iosifescu DV. Neuropeptide Y in PTSD, MDD, and chronic stress: a systematic review and meta-analysis. J Neurosci Res, 2020, 98(5): 950-963.
27.	Nogueiras R, Sabio G. Brain JNK and metabolic disease. Diabetologia, 2021, 64(2): 265-274.
28.	Razolli DS, de Araújo TM, Sant Apos Ana MR, et al. Proopiomelanocortin Processing in the hypothalamus is directly regulated by saturated fat: implications for the development of obesity. Neuroendocrinology, 2020, 110(1/2): 92-104.
29.	Muller PA, Matheis F, Schneeberger M, et al. Microbiota-modulated CART⁺ enteric neurons autonomously regulate blood glucose. Science, 2020, 370(6514): 314-321.
30.	Fearon KC, Glass DJ, Guttridge DC. Cancer cachexia: mediators, signaling, and metabolic pathways. Cell Metab, 2012, 16(2): 153-166.
31.	Petruzzelli M, Wagner EF. Mechanisms of metabolic dysfunction in cancer-associated cachexia. Genes Dev, 2016, 30(5): 489-501.
32.	Malik JS, Yennurajalingam S. Prokinetics and ghrelin for the management of cancer cachexia syndrome. Ann Palliat Med, 2019, 8(1): 80-85.
33.	Ma DW, Cho Y, Jeon MJ, et al. Relationship between sarcopenia and prognosis in patient with concurrent chemo-radiation therapy for esophageal cancer. Front Oncol, 2019, 9: 366.
34.	Feather CE, Lees JG, Makker PGS, et al. Oxaliplatin induces muscle loss and muscle-specific molecular changes in mice. Muscle Nerve, 2018, 57(4): 650-658.
35.	Oflazoglu U, Alacacioglu A, Varol U, et al. Chemotherapy-induced sarcopenia in newly diagnosed cancer patients: Izmir Oncology Group (IZOG) study. Support Care Cancer, 2020, 28(6): 2899-2910.
36.	Hiensch AE, Bolam KA, Mijwel S, et al. Doxorubicin-induced skeletal muscle atrophy: elucidating the underlying molecular pathways. Acta Physiol (Oxf), 2020, 229(2): e13400.
37.	Guo B, Bennet D, Belcher DJ, et al. Chemotherapy agents reduce protein synthesis and ribosomal capacity in myotubes independent of oxidative stress. Am J Physiol Cell Physiol, 2021, 321(6): C1000-C1009.
38.	Fang Z, Shang L, Li L. Impact of low skeletal muscle mass on complications and survival for gastric cancer: a propensity score matching analysis. Front Surg, 2022, 9: 901142.
39.	Matsui R, Inaki N, Tsuji T, et al. Impact of preoperative handgrip strength on postoperative outcome after radical gastrectomy for gastric cancer patients. J Clin Med, 2022, 11(23): 7129.
40.	Chen F, Chi J, Liu Y, et al. Impact of preoperative sarcopenia on postoperative complications and prognosis of gastric cancer resection: a meta-analysis of cohort studies. Arch Gerontol Geriatr, 2022, 98: 104534.
41.	Lee JK, Park YS, Lee K, et al. Prognostic significance of surgery-induced sarcopenia in the survival of gastric cancer patients: a sex-specific analysis. J Cachexia Sarcopenia Muscle, 2021, 12(6): 1897-1907.
42.	Prado CM, Lima IS, Baracos VE, et al. An exploratory study of body composition as a determinant of epirubicin pharmacokinetics and toxicity. Cancer Chemother Pharmacol, 2011, 67(1): 93-101.
43.	Lee J, Kim ST, Kim K, et al. Tumor genomic profiling guides patients with metastatic gastric cancer to targeted treatment: the VIKTORY umbrella trial. Cancer Discov, 2019, 9(10): 1388-1405.
44.	Kim YY, Lee J, Jeong WK, et al. Prognostic significance of sarcopenia in microsatellite-stable gastric cancer patients treated with programmed death-1 inhibitors. Gastric Cancer, 2021, 24(2): 457-466.
45.	Robinson SM, Reginster JY , Rizzoli R, et al. Does nutrition play a role in the prevention and management of sarcopenia?. Clin Nutr, 2018, 37(4): 1121-1132.
46.	Xu D, Lu Y, Yang X, et al. Effects of fish oil-derived n-3 polyunsaturated fatty acid on body composition, muscle strength and physical performance in older people: a secondary analysis of a randomised, double-blind, placebo-controlled trial. Age Ageing, 2022, 51(12): afac274.
47.	Anton SD, Hida A, Mankowski R, et al. Nutrition and exercise in sarcopenia. Curr Protein Pept Sci, 2018, 19(7): 649-667.
48.	Carcelén-Fraile MDC, Lorenzo-Nocino MF, Afanador-Restrepo DF, et al. Effects of different intervention combined with resistance training on musculoskeletal health in older male adults with sarcopenia: a systematic review. Front Public Health, 2023, 10: 1037464.
49.	Mellen RH, Girotto OS, Marques EB, et al. Insights into pathogenesis, nutritional and drug approach in sarcopenia: a systematic review. Biomedicines, 2023, 11(1): 136.
50.	Hu BA, Li YL, Han HT, et al. Stimulation of soluble guanylate cyclase by vericiguat reduces skeletal muscle atrophy of mice following chemotherapy. Front Pharmacol, 2023, 14: 1112123.

1. Sung H, Ferlay J, Siegel RL, et al. Global Cancer Statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin, 2021, 71(3): 209-249.
2. Cruz-Jentoft AJ, Bahat G, Bauer J, et al. Sarcopenia: revised European consensus on definition and diagnosis. Age Ageing, 2019, 48(1): 16-31.
3. Juez LD, Priego P, Bajawi M, et al. Impact of sarcopenic obesity on long-term cancer outcomes and postoperative complications after gastrectomy for gastric cancer. J Gastrointest Surg, 2023, 27(1): 35-46.
4. Kuwada K, Kuroda S, Kikuchi S, et al. Clinical impact of sarcopenia on gastric cancer. Anticancer Res, 2019, 39(5): 2241-2249.
5. Kim YM, Kim JH, Baik SJ, et al. Sarcopenia and sarcopenic obesity as novel risk factors for gastric carcinogenesis: a health checkup cohort study. Front Oncol, 2019, 9: 1249.
6. Petrelli F, Cortellini A, Indini A, et al. Association of obesity with survival outcomes in patients with cancer: a systematic review and meta-analysis. JAMA Netw Open, 2021, 4(3): e213520.
7. De A, Kumari S, Kaur A, et al. Hand-grip strength as a screening tool for sarcopenia in males with decompensated cirrhosis. Indian J Gastroenterol, 2022, 41(3): 284-291.
8. Cruz-Jentoft AJ, Sayer AA. Sarcopenia. Lancet, 2019, 393(10191): 2636-2646.
9. Stringer HJ, Wilson D. The role of ultrasound as a diagnostic tool for sarcopenia. J Frailty Aging, 2018, 7(4): 258-261.
10. Perkisas S, Baudry S, Bauer J, et al. Application of ultrasound for muscle assessment in sarcopenia: towards standardized measurements. Eur Geriatr Med, 2018, 9(6): 739-757.
11. Gonzalez MC, Barbosa-Silva TG, Heymsfield SB. Bioelectrical impedance analysis in the assessment of sarcopenia. Curr Opin Clin Nutr Metab Care, 2018, 21(5): 366-374.
12. Zhao WY, Zhang Y, Hou LS, et al. The association between systemic inflammatory markers and sarcopenia: results from the west china health and aging trend study (WCHAT). Arch Gerontol Geriatr, 2021, 92: 104262.
13. Bullock AF, Greenley SL, McKenzie GAG, et al. Relationship between markers of malnutrition and clinical outcomes in older adults with cancer: systematic review, narrative synthesis and meta-analysis. Eur J Clin Nutr, 2020, 74(11): 1519-1535.
14. Vaupel P, Multhoff G. Revisiting the Warburg effect: historical dogma versus current understanding. J Physiol, 2021, 599(6): 1745-1757.
15. Tambay V, Raymond VA, Bilodeau M. MYC rules: leading glutamine metabolism toward a distinct cancer cell phenotype. Cancers (Basel), 2021, 13(17): 4484.
16. Jiang P, Du W, Wang X, et al. p53 regulates biosynthesis through direct inactivation of glucose-6-phosphate dehydrogenase. Nat Cell Biol, 2011, 13(3): 310-316.
17. Elson DA, Ryan HE, Snow JW, et al. Coordinate up-regulation of hypoxia inducible factor (HIF)-1alpha and HIF-1 target genes during multi-stage epidermal carcinogenesis and wound healing. Cancer Res, 2000, 60(21): 6189-6195.
18. Akash MSH, Rehman K, Liaqat A. Tumor necrosis factor-alpha: role in development of insulin resistance and pathogenesis of type 2 diabetes mellitus. J Cell Biochem, 2018, 119(1): 105-110.
19. Argilés JM, López-Soriano FJ, Busquets S. Mediators of cachexia in cancer patients. Nutrition, 2019, 66: 11-15.
20. Tisdale MJ. Mechanisms of cancer cachexia. Physiol Rev, 2009, 89(2): 381-410.
21. Mirza KA, Tisdale MJ. Functional identity of receptors for proteolysis-inducing factor on human and murine skeletal muscle. Br J Cancer, 2014, 111(5): 903-908.
22. Abrigo J, Simon F, Cabrera D, et al. Mitochondrial dysfunction in skeletal muscle pathologies. Curr Protein Pept Sci, 2019, 20(6): 536-546.
23. Roeland EJ, Bohlke K, Baracos VE, et al. Management of cancer cachexia: ASCO guideline. J Clin Oncol, 2020, 38(21): 2438-2453.
24. Seki T, Yang Y, Sun X, et al. Brown-fat-mediated tumour suppression by cold-altered global metabolism. Nature, 2022, 608(7922): 421-428.
25. Nguyen TD, Miyatake Y, Yoshida T, et al. Tumor-secreted proliferin-1 regulates adipogenesis and lipolysis in cachexia. Int J Cancer, 2020, 148(8): 1982-1992.
26. Tural U, Iosifescu DV. Neuropeptide Y in PTSD, MDD, and chronic stress: a systematic review and meta-analysis. J Neurosci Res, 2020, 98(5): 950-963.
27. Nogueiras R, Sabio G. Brain JNK and metabolic disease. Diabetologia, 2021, 64(2): 265-274.
28. Razolli DS, de Araújo TM, Sant Apos Ana MR, et al. Proopiomelanocortin Processing in the hypothalamus is directly regulated by saturated fat: implications for the development of obesity. Neuroendocrinology, 2020, 110(1/2): 92-104.
29. Muller PA, Matheis F, Schneeberger M, et al. Microbiota-modulated CART⁺ enteric neurons autonomously regulate blood glucose. Science, 2020, 370(6514): 314-321.
30. Fearon KC, Glass DJ, Guttridge DC. Cancer cachexia: mediators, signaling, and metabolic pathways. Cell Metab, 2012, 16(2): 153-166.
31. Petruzzelli M, Wagner EF. Mechanisms of metabolic dysfunction in cancer-associated cachexia. Genes Dev, 2016, 30(5): 489-501.
32. Malik JS, Yennurajalingam S. Prokinetics and ghrelin for the management of cancer cachexia syndrome. Ann Palliat Med, 2019, 8(1): 80-85.
33. Ma DW, Cho Y, Jeon MJ, et al. Relationship between sarcopenia and prognosis in patient with concurrent chemo-radiation therapy for esophageal cancer. Front Oncol, 2019, 9: 366.
34. Feather CE, Lees JG, Makker PGS, et al. Oxaliplatin induces muscle loss and muscle-specific molecular changes in mice. Muscle Nerve, 2018, 57(4): 650-658.
35. Oflazoglu U, Alacacioglu A, Varol U, et al. Chemotherapy-induced sarcopenia in newly diagnosed cancer patients: Izmir Oncology Group (IZOG) study. Support Care Cancer, 2020, 28(6): 2899-2910.
36. Hiensch AE, Bolam KA, Mijwel S, et al. Doxorubicin-induced skeletal muscle atrophy: elucidating the underlying molecular pathways. Acta Physiol (Oxf), 2020, 229(2): e13400.
37. Guo B, Bennet D, Belcher DJ, et al. Chemotherapy agents reduce protein synthesis and ribosomal capacity in myotubes independent of oxidative stress. Am J Physiol Cell Physiol, 2021, 321(6): C1000-C1009.
38. Fang Z, Shang L, Li L. Impact of low skeletal muscle mass on complications and survival for gastric cancer: a propensity score matching analysis. Front Surg, 2022, 9: 901142.
39. Matsui R, Inaki N, Tsuji T, et al. Impact of preoperative handgrip strength on postoperative outcome after radical gastrectomy for gastric cancer patients. J Clin Med, 2022, 11(23): 7129.
40. Chen F, Chi J, Liu Y, et al. Impact of preoperative sarcopenia on postoperative complications and prognosis of gastric cancer resection: a meta-analysis of cohort studies. Arch Gerontol Geriatr, 2022, 98: 104534.
41. Lee JK, Park YS, Lee K, et al. Prognostic significance of surgery-induced sarcopenia in the survival of gastric cancer patients: a sex-specific analysis. J Cachexia Sarcopenia Muscle, 2021, 12(6): 1897-1907.
42. Prado CM, Lima IS, Baracos VE, et al. An exploratory study of body composition as a determinant of epirubicin pharmacokinetics and toxicity. Cancer Chemother Pharmacol, 2011, 67(1): 93-101.
43. Lee J, Kim ST, Kim K, et al. Tumor genomic profiling guides patients with metastatic gastric cancer to targeted treatment: the VIKTORY umbrella trial. Cancer Discov, 2019, 9(10): 1388-1405.
44. Kim YY, Lee J, Jeong WK, et al. Prognostic significance of sarcopenia in microsatellite-stable gastric cancer patients treated with programmed death-1 inhibitors. Gastric Cancer, 2021, 24(2): 457-466.
45. Robinson SM, Reginster JY , Rizzoli R, et al. Does nutrition play a role in the prevention and management of sarcopenia?. Clin Nutr, 2018, 37(4): 1121-1132.
46. Xu D, Lu Y, Yang X, et al. Effects of fish oil-derived n-3 polyunsaturated fatty acid on body composition, muscle strength and physical performance in older people: a secondary analysis of a randomised, double-blind, placebo-controlled trial. Age Ageing, 2022, 51(12): afac274.
47. Anton SD, Hida A, Mankowski R, et al. Nutrition and exercise in sarcopenia. Curr Protein Pept Sci, 2018, 19(7): 649-667.
48. Carcelén-Fraile MDC, Lorenzo-Nocino MF, Afanador-Restrepo DF, et al. Effects of different intervention combined with resistance training on musculoskeletal health in older male adults with sarcopenia: a systematic review. Front Public Health, 2023, 10: 1037464.
49. Mellen RH, Girotto OS, Marques EB, et al. Insights into pathogenesis, nutritional and drug approach in sarcopenia: a systematic review. Biomedicines, 2023, 11(1): 136.
50. Hu BA, Li YL, Han HT, et al. Stimulation of soluble guanylate cyclase by vericiguat reduces skeletal muscle atrophy of mice following chemotherapy. Front Pharmacol, 2023, 14: 1112123.

West China Medical Journal

Correlation between sarcopenia and gastric cancer

Abstract Full text Figures/Tables Video References Cited by

Previous Article

Next Article

Format

Content